Iterum Therapeutics plc
ITRMF
Sailaja Puttagunta
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Sailaja Puttagunta
Iterum Therapeutics plc reported in an 8-K filed May 31, 2024 that Sailaja Puttagunta resigned as Chief Medical Officer, effective May 31, 2024. Iterum Therapeutics plc reported in an 8-K filed May 10, 2024 that Sailaja Puttagunta resigned as Chief Medical Officer, effective May 31, 2024.
“Dr. Puttagunta, whose previously announced resignation as CMO is effective as of May 31, 2024, will serve as a consultant to ITIL providing general support and advice throughout the regulatory review period of the Company's recently resubmitted new drug application for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women (the "Services").”
“On May 8, 2024, Sailaja Puttagunta M.D. notified Iterum Therapeutics plc (the "Company") of her decision to resign as Chief Medical Officer the Company, effective May 31, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Iterum Therapeutics plc (ITRMF)
Proxy statement
Start not stated–2024-05-31
-
Iterum Therapeutics plc (ITRMF)
Proxy statement
Start not stated–2024-05-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.